This article is Part 3 of a review series covering all of the initial public offerings for the biotech and pharmaceutical industries in 2021. Part 1 provided an overview of 2021 IPOs by therapy area, technology, and therapeutic class. Part 2 provided an overview of 2021 IPOs by therapeutic area.
This short article takes a deeper look into the 2021 IPOs for conventional small molecules being developed by oncology-focused companies including:
- Companies by asset class of focus and primary indication
- Lead molecules, mechanisms of action, and structures where available
- Development stage at IPO
- IPO proceeds
- A company spotlight
this content is exclusive to
Premium members
Upgrade to a Premium Drug Hunter membership to unlock the full content and start reading now.
